Dr Zvi Margaliot, MD | |
15390 Nw Cornell Rd Ste 225, Beaverton, OR 97006-5627 | |
(503) 601-2910 | |
(503) 601-2910 |
Full Name | Dr Zvi Margaliot |
---|---|
Gender | Male |
Speciality | Plastic Surgery - Surgery Of The Hand |
Location | 15390 Nw Cornell Rd Ste 225, Beaverton, Oregon |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1720507007 | NPI | - | NPPES |
MD183826 | Other | OR | OMB |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2082S0105X | Plastic Surgery - Surgery Of The Hand | MD183826 (Oregon) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Zvi Margaliot, MD 15390 Nw Cornell Rd Ste 225, Beaverton, OR 97006-5627 Ph: (503) 601-2910 | Dr Zvi Margaliot, MD 15390 Nw Cornell Rd Ste 225, Beaverton, OR 97006-5627 Ph: (503) 601-2910 |
News Archive
EnVivo Pharmaceuticals today announced it has discovered that EVP-6124, its alpha-7 nicotinic acetylcholine receptor agonist, possesses a novel mechanism not previously seen in the scientific community: it acts as a co-agonist with Acetylcholine (ACh) to enhance cognition.
American Heart Association CEO Nancy Brown issued the following statement today on new commitments from McDonald's and the Alliance for a Healthier Generation.
A diet created by researchers at Rush University Medical Center may help substantially slow cognitive decline in stroke survivors, according to preliminary research presented on Jan. 25, at the American Stroke Association's International Stroke Conference 2018 in Los Angeles.
With just two days to negotiate an agreement with Republican lawmakers before a potential government shutdown, Gov. Mark Dayton and Republican leaders are trying to find additional cuts in health and human services spending, the fastest-growing part of state government.
LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".
› Verified 2 days ago